PatentsUSA
House Subcommittee to Examine Impact of Trump-Era Tariffs and Pricing Policies on Pharmaceutical Patents and Patient Access
The Trump administration’s imposition of 100% tariffs on patented pharmaceuticals, combined with efforts to align U.S. drug prices with the lowest global rates, has intensified debate over pharmaceutical patent protections and patient affordability. On June 3, 2026, the House Judiciary Subcommittee on Courts, Intellec…
Wednesday, June 3, 2026